GILD the goal is still in the hunt and 4 and 6-week treatment duration that leverage all of HCV treatments.
Best is ACH-3102, ACH-3422, and Sovaprevir ONLY.....
R this funds sleeping ?
Kopernik held 16.56 million shares of the KGC at the end of the first quarter with a market value of $37.10 million.
First Eagle Investment Management and Renaissance Technologies are among the primary investors OF NYSE:KGC.
Need some boost ...
KGC is the seventh-largest gold company in the world, with its primary operations in the United States, Brazil, Ghana, Chile, Russia, and Mauritania.
Kinross Gold Corporation (USA) (NYSE:KGC) is the second largest basic materials stock holding of the fund. It is the seventh-largest gold company in the world, with its primary operations in the United States, Brazil, Ghana, Chile, Russia, and Mauritania. Kopernik held 16.56 million shares of the gold producer at the end of the first quarter with a market value of $37.10 million. Kinross Gold Corporation (USA) (NYSE:KGC) reported net revenue of $781.4 million in the first quarter of 2015 against revenue of $817.4 million in the prior year’s quarter. Net earnings were lower as well, at $15.3 million in comparison to last year’s quarterly earnings of $34.1 million. First Eagle Investment Management and Renaissance Technologies are among the primary investors of Kinross Gold Corporation (USA) (NYSE:KGC).
Gilead and AbbVie have forced out earlier standard remedies with oral combos that are much easier to tolerate and much more likely to provide a lasting cure. The goal now is to find ways to do it quicker and with less expense, providing an opening for some of the companies still in the hunt.
William Blair analyst Y. Katherine Xu offered some interesting commentary on Achillion.......... Achillion came out on top with new trial results which demonstrated that a combination of its NS5A inhibitor and Gilead's Sovaldi triggered a 6-week cure among all of the patients in a small study. And now researchers are using the data to set the stage to see if the results can be replicated even faster in a 4-week trial.
VRTX so far, the vote looks positive to me. the caveat, of course, is that everything can change once the panel starts to discuss and deliberate. The afternoon session is always interesting.
Reassessing capex budgets
Barrick Gold (ABX) is reassessing its 2015–2016 capital budget with a view to making capital allocation more strict. The company says it will review individual projects against a hurdle rate of 15%.
Barrick expects the ROIC (return on invested capital) on its overall portfolio to be 10% to 15% over the metal price cycle. The company’s compensation plan is also weighed by 20% toward meeting annual 10% to 15% ROIC targets.